Fledgling Recodagen gets first venture round

Seattle's Accelerator has a new fledgling biotech company on its hands. Recodagen is taking flight with an undisclosed amount of money from a Series A venture round. The cash is coming from Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners and WRF Capital. The biotech start-up will work out of an Accelerator facility with technology licensed from Washington State University. It will focus on the genetic mechanism involved in metastasis and the technology developed at Washington State by J. Suzanne Lindsey, who will move to Seattle and become research chief at the company. Recodagen is starting out with three workers.

- read the report from the Seattle Times

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.